Skip to content
10-K

Annual Report

BIOCEPT, INC.

0000950170-23-013109

← back to feed
Filed
Apr 17, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Apr 13, 2023 17.78M sh
Shares Diluted FY 2022 · Dec 31, 2022 16.95M sh
Shares Diluted FY 2022 · Dec 31, 2021 14.78M sh
Capex FY 2022 · Dec 31, 2022 $807K
Capex FY 2022 · Dec 31, 2021 $1.57M
Operating Cash Flow FY 2022 · Dec 31, 2022 −$13.29M
Operating Cash Flow FY 2022 · Dec 31, 2021 $3.69M
Stockholders Equity FY 2022 · Dec 31, 2022 $8.86M
Stockholders Equity FY 2022 · Dec 31, 2021 $37.48M
Stockholders Equity restated FY 2022 · Dec 31, 2020 $23.69M
Current Liabilities FY 2022 · Dec 31, 2022 $5.51M
Current Liabilities FY 2022 · Dec 31, 2021 $11.77M
Total Liabilities FY 2022 · Dec 31, 2022 $22.01M
Total Liabilities FY 2022 · Dec 31, 2021 $22.94M
Current Assets FY 2022 · Dec 31, 2022 $16.34M
Current Assets FY 2022 · Dec 31, 2021 $45.69M
Total Assets FY 2022 · Dec 31, 2022 $30.87M
Total Assets FY 2022 · Dec 31, 2021 $60.42M
Eps Diluted FY 2022 · Dec 31, 2022 −$1.89
Eps Diluted FY 2022 · Dec 31, 2021 −$0.19
Eps Basic FY 2022 · Dec 31, 2022 −$1.89
Eps Basic FY 2022 · Dec 31, 2021 −$0.19
Sga Expense FY 2022 · Dec 31, 2022 $16.11M
Sga Expense FY 2022 · Dec 31, 2021 $12.61M
Rd Expense FY 2022 · Dec 31, 2022 $6.16M
Rd Expense FY 2022 · Dec 31, 2021 $4.96M
Net Income FY 2022 · Dec 31, 2022 −$32.09M
Net Income FY 2022 · Dec 31, 2021 −$2.82M
Operating Income FY 2022 · Dec 31, 2022 −$31.98M
Operating Income FY 2022 · Dec 31, 2021 −$2.41M
Cost Of Revenue FY 2022 · Dec 31, 2022 $28.44M
Cost Of Revenue FY 2022 · Dec 31, 2021 $37.76M
Revenue FY 2022 · Dec 31, 2022 $25.86M
Revenue FY 2022 · Dec 31, 2021 $61.25M